Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation for Ulcerative Colitis Using Healthy Donors From Yunnan Dai and Han Nationalities
NCT07814456Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, randomised trial of allogeneic fecal microbiota in ulcerative colitis (UC) (2 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoint: Rate of clinical and endoscopic remission at 12 weeks. Started Feb 2026; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07814456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814456.